ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bind And Amgen To Inhibit Kinases

by Ann M. Thayer
January 14, 2013 | APPEARED IN VOLUME 91, ISSUE 2

Bind Biosciences will work with Amgen to develop kinase inhibitor nanomedicines to treat a range of solid tumors. Cambridge, Mass.-based Bind says it could receive up-front and development milestone payments totaling $46.5 million and up to $134 million more for regulatory and sales milestones. Bind is developing targeted and programmable therapeutics it calls Accurins. The partners are looking to develop a new Accurin around a proprietary kinase inhibitor from Amgen.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment